CANF vs. NXTC, INAB, LSTA, SNTI, LIAN, CARM, GELS, LPCN, APRE, and LPTX
Should you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include NextCure (NXTC), IN8bio (INAB), Lisata Therapeutics (LSTA), Senti Biosciences (SNTI), LianBio (LIAN), Carisma Therapeutics (CARM), Gelteq (GELS), Lipocine (LPCN), Aprea Therapeutics (APRE), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry.
Can-Fite BioPharma vs.
NextCure (NASDAQ:NXTC) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Can-Fite BioPharma's return on equity of 0.00% beat NextCure's return on equity.
NextCure has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
NextCure presently has a consensus price target of $4.00, suggesting a potential upside of 453.33%. Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 673.48%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than NextCure.
Can-Fite BioPharma has higher revenue and earnings than NextCure. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, Can-Fite BioPharma had 6 more articles in the media than NextCure. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 0 mentions for NextCure. Can-Fite BioPharma's average media sentiment score of 0.17 beat NextCure's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.
42.7% of NextCure shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
NextCure received 73 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 64.52% of users gave NextCure an outperform vote while only 9.86% of users gave Can-Fite BioPharma an outperform vote.
Summary
Can-Fite BioPharma beats NextCure on 11 of the 16 factors compared between the two stocks.
Get Can-Fite BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Can-Fite BioPharma Competitors List
Related Companies and Tools
This page (NYSE:CANF) was last updated on 2/22/2025 by MarketBeat.com Staff
